12 Best Absci Alternatives & Competitors (2026)

Twist Bioscience provides synthetic DNA libraries and NGS-based antibody discovery tools for custom biologics development. It enables large library construction and sequencing for binder identification across therapeutic areas. In contrast to Abalone Bio's function-first FAST platform measuring activity in parallel for GPCRs, Twist focuses on library diversity and binding workflows without integrated massive functional assays or activity-trained AI. This makes Twist suitable for initial library generation but less competitive for discovering rare activating antibodies where Abalone Bio's datasets unlock new targets.

Schrödinger provides physics-based molecular simulation software used for drug discovery across pharma and biotech. Its platform excels at structure-based design and predictive modeling with broad small-molecule coverage. Unlike Nabla Bio's integrated generative antibody focus and owned wet-lab data engine, Schrödinger primarily licenses computational tools that customers combine with external experimental resources, resulting in different cost structures and validation workflows.

Recursion operates a large-scale automated wet-lab platform generating proprietary biological data to train AI models for drug discovery. It covers multiple modalities and has an internal pipeline. Unlike Nabla Bio's focused antibody design engine, Recursion emphasizes phenotypic screening breadth and operates at greater scale with different partnership economics.

AbCellera is a leading antibody discovery company using single-cell screening and AI to identify binders from immune repertoires at high speed. It excels in rapid hit identification for traditional targets and has supported multiple clinical programs through partnerships. Unlike Abalone Bio's focus on functional activation of GPCRs via massive parallel activity assays and survival-linked yeast, AbCellera prioritizes binding affinity and structural characterization with smaller functional follow-up. Its platform suits high-throughput discovery but lacks Abalone Bio's 100M-scale activity datasets for training AI on activators, making it less ideal for hard-to-drug GPCR modulation where precise function is required over inhibition.

AbCellera is a leading antibody discovery company using single-cell screening and AI to identify binders from immune repertoires at high speed. It excels in rapid hit identification for traditional targets and has supported multiple clinical programs through partnerships. Unlike Abalone Bio's focus on functional activation of GPCRs via massive parallel activity assays and survival-linked yeast, AbCellera prioritizes binding affinity and structural characterization with smaller functional follow-up. Its platform suits high-throughput discovery but lacks Abalone Bio's 100M-scale activity datasets for training AI on activators, making it less ideal for hard-to-drug GPCR modulation where precise function is required over inhibition.

Insilico Medicine runs an end-to-end AI platform for target discovery through clinical candidate nomination, covering multiple disease areas. It has advanced several AI-designed molecules into human trials. Compared with Nabla Bio, Insilico offers wider therapeutic modality exploration and later-stage clinical momentum but maintains a less specialized emphasis on antibody developability testing at the scale Nabla Bio integrates internally.

Exscientia applies AI to precision design of small-molecule drugs and has multiple clinical-stage assets. Its platform emphasizes patient tissue data and automated design cycles. Relative to Nabla Bio's antibody-centric generative approach and fully owned dry/wet-lab stack, Exscientia focuses more on small molecules and has historically relied on partnered experimental validation rather than a single integrated engine.

Adimab offers yeast-based antibody discovery and optimization services emphasizing high-affinity binders and engineering for pharma partners. It leverages display technologies for rapid affinity maturation across diverse targets. Compared to Abalone Bio, Adimab centers on binding and developability rather than direct functional activity screening at 100M scale. Its yeast platform shares some similarities but does not link survival to GPCR activation or generate activity datasets for AI design of agonists. Abalone Bio's FAST approach provides an edge for activating challenging receptors where Adimab's methods may require extensive secondary assays.

Atomwise uses deep learning for structure-based small-molecule screening and design, serving multiple pharma partners. It provides large-scale virtual screening services. In contrast to Nabla Bio's de novo antibody generation paired with patient-relevant assays, Atomwise centers on small-molecule hit finding and typically operates without an in-house large-scale human biology testing infrastructure.

BenevolentAI applies machine learning to knowledge graphs and experimental data for target identification and molecule design, primarily in small molecules. Its approach differs from Nabla Bio by prioritizing disease mechanism mining over antibody-specific generative design and by relying more on partner labs for validation.

Generate Biomedicines develops a generative biology platform focused on de novo protein and antibody therapeutics. It maintains an integrated computational and experimental engine. Compared with Nabla Bio, Generate has disclosed larger financing and broader modality ambitions while sharing the core goal of designing functional proteins directly from models with internal testing.